Gilead Sciences (GILD) Is Among The Best Extremely Profitable Stocks To Buy According To Wall Street Analysts
Key takeaways
- (NASDAQ:GILD) ranks among the best extremely profitable stocks to buy according to Wall Street analysts.
- A technician testing a newly developed immunotherapy drug in a clinical laboratory.
- On May 8, 2026, Truist raised its price target on Gilead Sciences, Inc.
Gilead Sciences (GILD) Is Among The Best Extremely Profitable Stocks To Buy According To Wall Street Analysts Faheem Tahir Fri, May 22, 2026 at 12:46 AM GMT+7 3 min read GILD TFC With a net income margin of 31.00% and upside potential of 24.20%, Gilead Sciences, Inc. (NASDAQ:GILD) ranks among the best extremely profitable stocks to buy according to Wall Street analysts. The company reported net income of $8.51 billion for the recently completed fiscal year (FY25). That momentum continued into 2026, drawing analyst attention.
A technician testing a newly developed immunotherapy drug in a clinical laboratory.
On May 8, 2026, Truist raised its price target on Gilead Sciences, Inc. (NASDAQ:GILD) to $157 from $155, while keeping a “Buy” rating on the shares. The firm pointed to the company’s Q1 top- and bottom-line beat, raised FY26 revenue guide, and continued strength in HIV portfolio, particularly Yeztugo.